Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of end-stage renal disease on the sedative effect of ciprofol
ChiCTR2200063628Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Sep 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ciprofol in end-stage kidney disease (ESKD) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Ciprofol dosage. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
ciprofol
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2200063628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063628.